[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA05003364A - Parche transdermico de 17(-estradiol/levonorgestrel para hormonoterapia restitutiva. - Google Patents

Parche transdermico de 17(-estradiol/levonorgestrel para hormonoterapia restitutiva.

Info

Publication number
MXPA05003364A
MXPA05003364A MXPA05003364A MXPA05003364A MXPA05003364A MX PA05003364 A MXPA05003364 A MX PA05003364A MX PA05003364 A MXPA05003364 A MX PA05003364A MX PA05003364 A MXPA05003364 A MX PA05003364A MX PA05003364 A MXPA05003364 A MX PA05003364A
Authority
MX
Mexico
Prior art keywords
estradiol
17beta
levonorgestrel
replacement therapy
hormone replacement
Prior art date
Application number
MXPA05003364A
Other languages
English (en)
Inventor
Yankov Vladimir
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA05003364A publication Critical patent/MXPA05003364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se relaciona con un metodo para reducir las concentraciones de trigliceridos en un paciente y llevar a cabo hormoterapia restitutiva, que comprende administrar de manera continua y transdermica una cantidad terapeutica eficaz, esencialmente constante, de una composicion que comprende un estradiol (17(-estradiol) y una progestina (levonorgestrel) (LNF)) en un portador farmaceuticamente aceptable.
MXPA05003364A 2002-09-30 2003-09-29 Parche transdermico de 17(-estradiol/levonorgestrel para hormonoterapia restitutiva. MXPA05003364A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/259,892 US20040062794A1 (en) 2002-09-30 2002-09-30 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
PCT/US2003/030493 WO2004030675A1 (en) 2002-09-30 2003-09-29 17β-ESTRADIOL/LEVONORGESTREL TRANSDERM PATCH FOR HORMONE REPLACEMENT THERAPY

Publications (1)

Publication Number Publication Date
MXPA05003364A true MXPA05003364A (es) 2005-10-05

Family

ID=32029580

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003364A MXPA05003364A (es) 2002-09-30 2003-09-29 Parche transdermico de 17(-estradiol/levonorgestrel para hormonoterapia restitutiva.

Country Status (11)

Country Link
US (1) US20040062794A1 (es)
EP (1) EP1545547A1 (es)
JP (1) JP2006508071A (es)
CN (1) CN1684690A (es)
AU (1) AU2003279000A1 (es)
BR (1) BR0314959A (es)
CA (1) CA2495055A1 (es)
IL (1) IL166678A0 (es)
MX (1) MXPA05003364A (es)
RU (1) RU2005113686A (es)
WO (1) WO2004030675A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7889336B2 (en) * 2008-02-01 2011-02-15 Vladimir Yankov Optical integrated nanospectrometer
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2018136161A1 (en) * 2016-12-05 2018-07-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4927687A (en) * 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4900734A (en) * 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
DE69420419T2 (de) * 1993-09-29 1999-12-23 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
GR1002079B (en) * 1994-07-26 1995-12-05 Lavipharm A E System of a special structure and composition for the rapid transdermal administration of oestrogens.
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US6551611B2 (en) * 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6132760A (en) * 1997-02-28 2000-10-17 3M Innovative Properties Company Transdermal device for the delivery of testosterone
US6193996B1 (en) * 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6312715B1 (en) * 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
MXPA00012844A (es) * 1998-07-07 2004-05-21 Transdermal Technologies Inc Composiciones para la liberacion transdermica rapida y sin irritacion de agentes farmaceuticamente activos y metodos para formular tales composiciones y liberar los mismos.
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers

Also Published As

Publication number Publication date
WO2004030675A1 (en) 2004-04-15
JP2006508071A (ja) 2006-03-09
US20040062794A1 (en) 2004-04-01
AU2003279000A1 (en) 2004-04-23
RU2005113686A (ru) 2006-01-20
CN1684690A (zh) 2005-10-19
CA2495055A1 (en) 2004-04-15
BR0314959A (pt) 2005-08-02
IL166678A0 (en) 2006-01-15
EP1545547A1 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
NZ311304A (en) Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
HK1106717A1 (en) Microparticles consisting of estradiol and cholesterol
YU54602A (sh) Drospirenon za terapiju zamene hormona
CA2431645A1 (en) Methods of treating hormonal deficiencies in women undergoing estrogen replacement therapy
MY152750A (en) Transdermal delivery system of hormones without penetration enhancers
AU3601897A (en) Novel formulations for the administration of fluoxetine
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
AP1625A (en) Hormonal composition based on a progesterone and an oestrogen and use thereof.
YU18099A (sh) Hormonalni preparat koji sadrži jedinjenje estrogena i progestativno jedinjenje
MXPA05003364A (es) Parche transdermico de 17(-estradiol/levonorgestrel para hormonoterapia restitutiva.
GB0201367D0 (en) Composition
Gallagher Moderation of the daily dose of HRT: prevention of osteoporosis
GB0003524D0 (en) Cytoprotective steroids (II)
Stevenson Optimising delivery systems for HRT
CA2529983A1 (en) Preoperative treatment of post operative pain
AU2001236529A1 (en) Combination therapy for cancer
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
JP2003522121A5 (es)
AP1707A (en) Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same.
Munoz OESCLIM®: an advanced delivery system for HRT
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére

Legal Events

Date Code Title Description
FA Abandonment or withdrawal